Phase 2 study for people with Lung Cancer

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 12 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Bristol-Myers Squibb
Registry number NCT07680764
Started 10 September 2026 Today 16 October 2026 Estimated completion 15 September 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Local Institution - 0074 Gosford NSW Not yet recruiting
Local Institution - 0134 Westmead NSW Not yet recruiting
Local Institution - 0167 Greenslopes QLD Not yet recruiting
Local Institution - 0100 Heidelberg VIC Not yet recruiting
St. John of God Murdoch Hospital Perth WA Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 12 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 160

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria

* Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.

* Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.

* Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.

* Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

* Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria

* Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.

* Participants must not have prior treatment with immuno-oncology therapies.

* Participants must not have untreated central nervous system (CNS) metastases.

* Other protocol-defined Inclusion/Exclusion criteria apply.

Dates on the record

Started 10 September 2026
Estimated completion 15 September 2028
Registry last updated 2 October 2026
Checked by Voxsanity 12 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 2 October 2026.
  • This page last checked by Voxsanity: 12 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.